Menu Search
Equities

Biontech SE

BNTX:NSQ

Biontech SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)112.80
  • Today's Change4.57 / 4.22%
  • Shares traded880.26k
  • 1 Year change+15.15%
  • Beta0.1977
Data delayed at least 15 minutes, as of Nov 22 2024 19:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Biontech SE's revenues fell -77.94% from 17.31bn to 3.82bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 9.43bn to 930.30m, a -90.14% decrease.
Gross margin87.71%
Net profit margin-15.36%
Operating margin-30.81%
Return on assets-2.09%
Return on equity-2.40%
Return on investment-2.32%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Biontech SE fell by 2.21bn. However, the company earned 5.37bn from its operations for a Cash Flow Margin of 140.65%. In addition the company used 6.95bn on investing activities and also paid 778.60m in financing cash flows.
Cash flow per share-1.11
Price/Cash flow per share--
Book value per share83.50
Tangible book value per share78.05
More ▼

Balance sheet in EURView more

Biontech SE appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio7.33
Quick ratio7.21
Total debt/total equity0.0128
Total debt/total capital0.0126
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.